抗血管内皮生长因子药物治疗新生血管性老年性黄斑变性应答不良及无应答现象机制研究的进展

Progress in the study of anti-vascular endothelial growth factor application for the treatment of neovascular age-related macular degeneration and the mechanism of poor and non-response

抗血管内皮生长因子（VEGF）药物治疗新生血管（CNV）性老年性黄斑变性（nAMD）的效果根据其视力和黄斑中心凹视网膜形态改变等疗效评价指标可出现不同的应答反应,包括应答不良与无应答现象.nAMD疾病自身以及治疗药物相关的基因、CNV发生发展的相关因子和组织解剖结构、药物效率及药代动力学特性等是抗VEGF药物治疗nAMD出现应答不良与无应答现象的可能相关影响因素.应答不良与无应答现象的形成机制是抗VEGF药物治疗nAMD的关注热点,值得进一步深入探讨.

According to the best corrected visual acuity and the morphological changes of the macular fovea,responses to the neovascular age-related macular degeneration （nAMD） who receive anti-vascular endothelial growth factor （VEGF） therapy show large variability,including poor and non-responders.Various factors will be reviewed to account for poor and non-response to anti-VEGF therapy,such as the related susceptibility genes,factors related with the development of choroidal neovascularization and morphologic parameters,pharmacokinetics and tachyphylaxis.The future research should focus on comprehensive assessment of factors affecting the efficacy of anti-VEGF therapy to improve the therapeutic outcome of nAMD.